Skip to content

Enriqueta Felip

Vall d'Hebron Hospital Universitari

3 papers in the Anchorcite directory, published between 2015 and 2018, cited 22,521 times in total.

ORCID profile

Research topics

Frequent co-authors

Papers

  1. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 9,473 citations

    BACKGROUND: Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity. METHODS: In this randomized, open-label, international phase 3 study, we assigned patients with nonsquamous non-small-cell lung cancer (NSCLC) that had…

  2. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine · 2018 · 6,754 citations

    BACKGROUND: First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the…

  3. Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 6,294 citations

    BACKGROUND: We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study. We also sought to define and validate an expression level of…

Metadata from OpenAlex (CC0).